[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |
Advanced search

United States Secondary Progressive Multiple Sclerosis Drug Market Report 2018

March 2018 | 110 pages | ID: UD19F72EBB8QEN
QYResearch

US$ 3,800.00

E-mail Delivery (PDF)

Download PDF Leaflet

Accepted cards
Wire Transfer
Checkout Later
Need Help? Ask a Question
In this report, the United States Secondary Progressive Multiple Sclerosis Drug market is valued at USD XX million in 2017 and is expected to reach USD XX million by the end of 2025, growing at a CAGR of XX% between 2017 and 2025.

Geographically, this report splits the United States market into seven regions:
  • The West
  • Southwest
  • The Middle Atlantic
  • New England
  • The South
  • The Midwest
  • with sales (volume), revenue (value), market share and growth rate of Secondary Progressive Multiple Sclerosis Drug in these regions, from 2013 to 2025 (forecast).
United States Secondary Progressive Multiple Sclerosis Drug market competition by top manufacturers/players, with Secondary Progressive Multiple Sclerosis Drug sales volume, price, revenue (Million USD) and market share for each manufacturer/player; the top players including
  • AB Science SA
  • Actelion Ltd
  • Biogen, Inc.
  • F. Hoffmann-La Roche Ltd.
  • Genzyme Corporation
  • Glialogix, Inc.
  • Immune Response BioPharma, Inc.
  • Innate Immunotherapeutics Ltd
  • Kyorin Pharmaceutical Co., Ltd.
  • Mallinckrodt Plc
  • MedDay SA
  • MedImmune, LLC
  • Merck KGaA
  • Meta-IQ ApS
  • Novartis AG
  • Opexa Therapeutics, Inc.
  • Xenetic Biosciences (UK) Limited
On the basis of product, this report displays the production, revenue, price, market share and growth rate of each type, primarily split into
  • Inebilizumab
  • GLX-1112
  • DC-TAB
  • Etomoxir
  • IB-MS
  • Others
On the basis on the end users/applications, this report focuses on the status and outlook for major applications/end users, sales volume, market share and growth rate for each application, including
  • Hospital
  • Clinic
  • Others
If you have any special requirements, please let us know and we will offer you the report as you want.
United States Secondary Progressive Multiple Sclerosis Drug Market Report 2018

1 SECONDARY PROGRESSIVE MULTIPLE SCLEROSIS DRUG OVERVIEW

1.1 Product Overview and Scope of Secondary Progressive Multiple Sclerosis Drug
1.2 Classification of Secondary Progressive Multiple Sclerosis Drug by Product Category
  1.2.1 United States Secondary Progressive Multiple Sclerosis Drug Market Size (Sales Volume) Comparison by Type (2013-2025)
  1.2.2 United States Secondary Progressive Multiple Sclerosis Drug Market Size (Sales Volume) Market Share by Type (Product Category) in 2017
  1.2.3 Inebilizumab
  1.2.4 GLX-1112
  1.2.5 DC-TAB
  1.2.6 Etomoxir
  1.2.7 IB-MS
  1.2.8 Others
1.3 United States Secondary Progressive Multiple Sclerosis Drug Market by Application/End Users
  1.3.1 United States Secondary Progressive Multiple Sclerosis Drug Market Size (Consumption) and Market Share Comparison by Application (2013-2025)
  1.3.2 Hospital
  1.3.3 Clinic
  1.3.4 Others
1.4 United States Secondary Progressive Multiple Sclerosis Drug Market by Region
  1.4.1 United States Secondary Progressive Multiple Sclerosis Drug Market Size (Value) Comparison by Region (2013-2025)
  1.4.2 The West Secondary Progressive Multiple Sclerosis Drug Status and Prospect (2013-2025)
  1.4.3 Southwest Secondary Progressive Multiple Sclerosis Drug Status and Prospect (2013-2025)
  1.4.4 The Middle Atlantic Secondary Progressive Multiple Sclerosis Drug Status and Prospect (2013-2025)
  1.4.5 New England Secondary Progressive Multiple Sclerosis Drug Status and Prospect (2013-2025)
  1.4.6 The South Secondary Progressive Multiple Sclerosis Drug Status and Prospect (2013-2025)
  1.4.7 The Midwest Secondary Progressive Multiple Sclerosis Drug Status and Prospect (2013-2025)
1.5 United States Market Size (Value and Volume) of Secondary Progressive Multiple Sclerosis Drug (2013-2025)
  1.5.1 United States Secondary Progressive Multiple Sclerosis Drug Sales and Growth Rate (2013-2025)
  1.5.2 United States Secondary Progressive Multiple Sclerosis Drug Revenue and Growth Rate (2013-2025)

2 UNITED STATES SECONDARY PROGRESSIVE MULTIPLE SCLEROSIS DRUG MARKET COMPETITION BY PLAYERS/SUPPLIERS

2.1 United States Secondary Progressive Multiple Sclerosis Drug Sales and Market Share of Key Players/Suppliers (2013-2018)
2.2 United States Secondary Progressive Multiple Sclerosis Drug Revenue and Share by Players/Suppliers (2013-2018)
2.3 United States Secondary Progressive Multiple Sclerosis Drug Average Price by Players/Suppliers (2013-2018)
2.4 United States Secondary Progressive Multiple Sclerosis Drug Market Competitive Situation and Trends
  2.4.1 United States Secondary Progressive Multiple Sclerosis Drug Market Concentration Rate
  2.4.2 United States Secondary Progressive Multiple Sclerosis Drug Market Share of Top 3 and Top 5 Players/Suppliers
  2.4.3 Mergers & Acquisitions, Expansion in United States Market
2.5 United States Players/Suppliers Secondary Progressive Multiple Sclerosis Drug Manufacturing Base Distribution, Sales Area, Product Type

3 UNITED STATES SECONDARY PROGRESSIVE MULTIPLE SCLEROSIS DRUG SALES (VOLUME) AND REVENUE (VALUE) BY REGION (2013-2018)

3.1 United States Secondary Progressive Multiple Sclerosis Drug Sales and Market Share by Region (2013-2018)
3.2 United States Secondary Progressive Multiple Sclerosis Drug Revenue and Market Share by Region (2013-2018)
3.3 United States Secondary Progressive Multiple Sclerosis Drug Price by Region (2013-2018)

4 UNITED STATES SECONDARY PROGRESSIVE MULTIPLE SCLEROSIS DRUG SALES (VOLUME) AND REVENUE (VALUE) BY TYPE (PRODUCT CATEGORY) (2013-2018)

4.1 United States Secondary Progressive Multiple Sclerosis Drug Sales and Market Share by Type (Product Category) (2013-2018)
4.2 United States Secondary Progressive Multiple Sclerosis Drug Revenue and Market Share by Type (2013-2018)
4.3 United States Secondary Progressive Multiple Sclerosis Drug Price by Type (2013-2018)
4.4 United States Secondary Progressive Multiple Sclerosis Drug Sales Growth Rate by Type (2013-2018)

5 UNITED STATES SECONDARY PROGRESSIVE MULTIPLE SCLEROSIS DRUG SALES (VOLUME) BY APPLICATION (2013-2018)

5.1 United States Secondary Progressive Multiple Sclerosis Drug Sales and Market Share by Application (2013-2018)
5.2 United States Secondary Progressive Multiple Sclerosis Drug Sales Growth Rate by Application (2013-2018)
5.3 Market Drivers and Opportunities

6 UNITED STATES SECONDARY PROGRESSIVE MULTIPLE SCLEROSIS DRUG PLAYERS/SUPPLIERS PROFILES AND SALES DATA

6.1 AB Science SA
  6.1.1 Company Basic Information, Manufacturing Base and Competitors
  6.1.2 Secondary Progressive Multiple Sclerosis Drug Product Category, Application and Specification
    6.1.2.1 Product A
    6.1.2.2 Product B
  6.1.3 AB Science SA Secondary Progressive Multiple Sclerosis Drug Sales, Revenue, Price and Gross Margin (2013-2018)
  6.1.4 Main Business/Business Overview
6.2 Actelion Ltd
  6.2.2 Secondary Progressive Multiple Sclerosis Drug Product Category, Application and Specification
    6.2.2.1 Product A
    6.2.2.2 Product B
  6.2.3 Actelion Ltd Secondary Progressive Multiple Sclerosis Drug Sales, Revenue, Price and Gross Margin (2013-2018)
  6.2.4 Main Business/Business Overview
6.3 Biogen, Inc.
  6.3.2 Secondary Progressive Multiple Sclerosis Drug Product Category, Application and Specification
    6.3.2.1 Product A
    6.3.2.2 Product B
  6.3.3 Biogen, Inc. Secondary Progressive Multiple Sclerosis Drug Sales, Revenue, Price and Gross Margin (2013-2018)
  6.3.4 Main Business/Business Overview
6.4 F. Hoffmann-La Roche Ltd.
  6.4.2 Secondary Progressive Multiple Sclerosis Drug Product Category, Application and Specification
    6.4.2.1 Product A
    6.4.2.2 Product B
  6.4.3 F. Hoffmann-La Roche Ltd. Secondary Progressive Multiple Sclerosis Drug Sales, Revenue, Price and Gross Margin (2013-2018)
  6.4.4 Main Business/Business Overview
6.5 Genzyme Corporation
  6.5.2 Secondary Progressive Multiple Sclerosis Drug Product Category, Application and Specification
    6.5.2.1 Product A
    6.5.2.2 Product B
  6.5.3 Genzyme Corporation Secondary Progressive Multiple Sclerosis Drug Sales, Revenue, Price and Gross Margin (2013-2018)
  6.5.4 Main Business/Business Overview
6.6 Glialogix, Inc.
  6.6.2 Secondary Progressive Multiple Sclerosis Drug Product Category, Application and Specification
    6.6.2.1 Product A
    6.6.2.2 Product B
  6.6.3 Glialogix, Inc. Secondary Progressive Multiple Sclerosis Drug Sales, Revenue, Price and Gross Margin (2013-2018)
  6.6.4 Main Business/Business Overview
6.7 Immune Response BioPharma, Inc.
  6.7.2 Secondary Progressive Multiple Sclerosis Drug Product Category, Application and Specification
    6.7.2.1 Product A
    6.7.2.2 Product B
  6.7.3 Immune Response BioPharma, Inc. Secondary Progressive Multiple Sclerosis Drug Sales, Revenue, Price and Gross Margin (2013-2018)
  6.7.4 Main Business/Business Overview
6.8 Innate Immunotherapeutics Ltd
  6.8.2 Secondary Progressive Multiple Sclerosis Drug Product Category, Application and Specification
    6.8.2.1 Product A
    6.8.2.2 Product B
  6.8.3 Innate Immunotherapeutics Ltd Secondary Progressive Multiple Sclerosis Drug Sales, Revenue, Price and Gross Margin (2013-2018)
  6.8.4 Main Business/Business Overview
6.9 Kyorin Pharmaceutical Co., Ltd.
  6.9.2 Secondary Progressive Multiple Sclerosis Drug Product Category, Application and Specification
    6.9.2.1 Product A
    6.9.2.2 Product B
  6.9.3 Kyorin Pharmaceutical Co., Ltd. Secondary Progressive Multiple Sclerosis Drug Sales, Revenue, Price and Gross Margin (2013-2018)
  6.9.4 Main Business/Business Overview
6.10 Mallinckrodt Plc
  6.10.2 Secondary Progressive Multiple Sclerosis Drug Product Category, Application and Specification
    6.10.2.1 Product A
    6.10.2.2 Product B
  6.10.3 Mallinckrodt Plc Secondary Progressive Multiple Sclerosis Drug Sales, Revenue, Price and Gross Margin (2013-2018)
  6.10.4 Main Business/Business Overview
6.11 MedDay SA
6.12 MedImmune, LLC
6.13 Merck KGaA
6.14 Meta-IQ ApS
6.15 Novartis AG
6.16 Opexa Therapeutics, Inc.
6.17 Xenetic Biosciences (UK) Limited

7 SECONDARY PROGRESSIVE MULTIPLE SCLEROSIS DRUG MANUFACTURING COST ANALYSIS

7.1 Secondary Progressive Multiple Sclerosis Drug Key Raw Materials Analysis
  7.1.1 Key Raw Materials
  7.1.2 Price Trend of Key Raw Materials
  7.1.3 Key Suppliers of Raw Materials
  7.1.4 Market Concentration Rate of Raw Materials
7.2 Proportion of Manufacturing Cost Structure
  7.2.1 Raw Materials
  7.2.2 Labor Cost
  7.2.3 Manufacturing Expenses
7.3 Manufacturing Process Analysis of Secondary Progressive Multiple Sclerosis Drug

8 INDUSTRIAL CHAIN, SOURCING STRATEGY AND DOWNSTREAM BUYERS

8.1 Secondary Progressive Multiple Sclerosis Drug Industrial Chain Analysis
8.2 Upstream Raw Materials Sourcing
8.3 Raw Materials Sources of Secondary Progressive Multiple Sclerosis Drug Major Manufacturers in 2017
8.4 Downstream Buyers

9 MARKETING STRATEGY ANALYSIS, DISTRIBUTORS/TRADERS

9.1 Marketing Channel
  9.1.1 Direct Marketing
  9.1.2 Indirect Marketing
  9.1.3 Marketing Channel Development Trend
9.2 Market Positioning
  9.2.1 Pricing Strategy
  9.2.2 Brand Strategy
  9.2.3 Target Client
9.3 Distributors/Traders List

10 MARKET EFFECT FACTORS ANALYSIS

10.1 Technology Progress/Risk
  10.1.1 Substitutes Threat
  10.1.2 Technology Progress in Related Industry
10.2 Consumer Needs/Customer Preference Change
10.3 Economic/Political Environmental Change

11 UNITED STATES SECONDARY PROGRESSIVE MULTIPLE SCLEROSIS DRUG MARKET SIZE (VALUE AND VOLUME) FORECAST (2018-2025)

11.1 United States Secondary Progressive Multiple Sclerosis Drug Sales Volume, Revenue Forecast (2018-2025)
11.2 United States Secondary Progressive Multiple Sclerosis Drug Sales Volume Forecast by Type (2018-2025)
11.3 United States Secondary Progressive Multiple Sclerosis Drug Sales Volume Forecast by Application (2018-2025)
11.4 United States Secondary Progressive Multiple Sclerosis Drug Sales Volume Forecast by Region (2018-2025)

12 RESEARCH FINDINGS AND CONCLUSION

13 APPENDIX

13.1 Methodology/Research Approach
  13.1.1 Research Programs/Design
  13.1.2 Market Size Estimation
  13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
  13.2.1 Secondary Sources
  13.2.2 Primary Sources
13.3 Disclaimer

The report requires updating with new data and is sent in 2-3 business days after order is placed.


LIST OF TABLES AND FIGURES

Figure Product Picture of Secondary Progressive Multiple Sclerosis Drug
Figure United States Secondary Progressive Multiple Sclerosis Drug Market Size (K Pcs) by Type (2013-2025)
Figure United States Secondary Progressive Multiple Sclerosis Drug Sales Volume Market Share by Type (Product Category) in 2017
Figure Inebilizumab Product Picture
Figure GLX-1112 Product Picture
Figure DC-TAB Product Picture
Figure Etomoxir Product Picture
Figure IB-MS Product Picture
Figure Others Product Picture
Figure United States Secondary Progressive Multiple Sclerosis Drug Market Size (K Pcs) by Application (2013-2025)
Figure United States Sales Market Share of Secondary Progressive Multiple Sclerosis Drug by Application in 2017
Figure Hospital Examples
Table Key Downstream Customer in Hospital
Figure Clinic Examples
Table Key Downstream Customer in Clinic
Figure Others Examples
Table Key Downstream Customer in Others
Figure United States Secondary Progressive Multiple Sclerosis Drug Market Size (Million USD) by Region (2013-2025)
Figure The West Secondary Progressive Multiple Sclerosis Drug Revenue (Million USD) and Growth Rate (2013-2025)
Figure Southwest Secondary Progressive Multiple Sclerosis Drug Revenue (Million USD) and Growth Rate (2013-2025)
Figure The Middle Atlantic Secondary Progressive Multiple Sclerosis Drug Revenue (Million USD) and Growth Rate (2013-2025)
Figure New England Secondary Progressive Multiple Sclerosis Drug Revenue (Million USD) and Growth Rate (2013-2025)
Figure The South of US Secondary Progressive Multiple Sclerosis Drug Revenue (Million USD) and Growth Rate (2013-2025)
Figure The Midwest Secondary Progressive Multiple Sclerosis Drug Revenue (Million USD) and Growth Rate (2013-2025)
Figure United States Secondary Progressive Multiple Sclerosis Drug Sales (K Pcs) and Growth Rate (2013-2025)
Figure United States Secondary Progressive Multiple Sclerosis Drug Revenue (Million USD) and Growth Rate (2013-2025)
Figure United States Secondary Progressive Multiple Sclerosis Drug Market Major Players Product Sales Volume (K Pcs) (2013-2018)
Table United States Secondary Progressive Multiple Sclerosis Drug Sales (K Pcs) of Key Players/Suppliers (2013-2018)
Table United States Secondary Progressive Multiple Sclerosis Drug Sales Share by Players/Suppliers (2013-2018)
Figure 2017 United States Secondary Progressive Multiple Sclerosis Drug Sales Share by Players/Suppliers
Figure 2017 United States Secondary Progressive Multiple Sclerosis Drug Sales Share by Players/Suppliers
Figure United States Secondary Progressive Multiple Sclerosis Drug Market Major Players Product Revenue (Million USD) (2013-2018)
Table United States Secondary Progressive Multiple Sclerosis Drug Revenue (Million USD) by Players/Suppliers (2013-2018)
Table United States Secondary Progressive Multiple Sclerosis Drug Revenue Share by Players/Suppliers (2013-2018)
Figure 2017 United States Secondary Progressive Multiple Sclerosis Drug Revenue Share by Players/Suppliers
Figure 2017 United States Secondary Progressive Multiple Sclerosis Drug Revenue Share by Players/Suppliers
Table United States Market Secondary Progressive Multiple Sclerosis Drug Average Price (USD/Pcs) of Key Players/Suppliers (2013-2018)
Figure United States Market Secondary Progressive Multiple Sclerosis Drug Average Price (USD/Pcs) of Key Players/Suppliers in 2017
Figure United States Secondary Progressive Multiple Sclerosis Drug Market Share of Top 3 Players/Suppliers
Figure United States Secondary Progressive Multiple Sclerosis Drug Market Share of Top 5 Players/Suppliers
Table United States Players/Suppliers Secondary Progressive Multiple Sclerosis Drug Manufacturing Base Distribution and Sales Area
Table United States Players/Suppliers Secondary Progressive Multiple Sclerosis Drug Product Category
Table United States Secondary Progressive Multiple Sclerosis Drug Sales (K Pcs) by Region (2013-2018)
Table United States Secondary Progressive Multiple Sclerosis Drug Sales Share by Region (2013-2018)
Figure United States Secondary Progressive Multiple Sclerosis Drug Sales Share by Region (2013-2018)
Figure United States Secondary Progressive Multiple Sclerosis Drug Sales Market Share by Region in 2017
Table United States Secondary Progressive Multiple Sclerosis Drug Revenue (Million USD) and Market Share by Region (2013-2018)
Table United States Secondary Progressive Multiple Sclerosis Drug Revenue Share by Region (2013-2018)
Figure United States Secondary Progressive Multiple Sclerosis Drug Revenue Market Share by Region (2013-2018)
Figure United States Secondary Progressive Multiple Sclerosis Drug Revenue Market Share by Region in 2017
Table United States Secondary Progressive Multiple Sclerosis Drug Price (USD/Pcs) by Region (2013-2018)
Table United States Secondary Progressive Multiple Sclerosis Drug Sales (K Pcs) by Type (2013-2018)
Table United States Secondary Progressive Multiple Sclerosis Drug Sales Share by Type (2013-2018)
Figure United States Secondary Progressive Multiple Sclerosis Drug Sales Share by Type (2013-2018)
Figure United States Secondary Progressive Multiple Sclerosis Drug Sales Market Share by Type in 2017
Table United States Secondary Progressive Multiple Sclerosis Drug Revenue (Million USD) and Market Share by Type (2013-2018)
Table United States Secondary Progressive Multiple Sclerosis Drug Revenue Share by Type (2013-2018)
Figure Revenue Market Share of Secondary Progressive Multiple Sclerosis Drug by Type (2013-2018)
Figure Revenue Market Share of Secondary Progressive Multiple Sclerosis Drug by Type in 2017
Table United States Secondary Progressive Multiple Sclerosis Drug Price (USD/Pcs) by Types (2013-2018)
Figure United States Secondary Progressive Multiple Sclerosis Drug Sales Growth Rate by Type (2013-2018)
Table United States Secondary Progressive Multiple Sclerosis Drug Sales (K Pcs) by Application (2013-2018)
Table United States Secondary Progressive Multiple Sclerosis Drug Sales Market Share by Application (2013-2018)
Figure United States Secondary Progressive Multiple Sclerosis Drug Sales Market Share by Application (2013-2018)
Figure United States Secondary Progressive Multiple Sclerosis Drug Sales Market Share by Application in 2017
Table United States Secondary Progressive Multiple Sclerosis Drug Sales Growth Rate by Application (2013-2018)
Figure United States Secondary Progressive Multiple Sclerosis Drug Sales Growth Rate by Application (2013-2018)
Table AB Science SA Basic Information List
Table AB Science SA Secondary Progressive Multiple Sclerosis Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2013-2018)
Figure AB Science SA Secondary Progressive Multiple Sclerosis Drug Sales Growth Rate (2013-2018)
Figure AB Science SA Secondary Progressive Multiple Sclerosis Drug Sales Market Share in United States (2013-2018)
Figure AB Science SA Secondary Progressive Multiple Sclerosis Drug Revenue Market Share in United States (2013-2018)
Table Actelion Ltd Basic Information List
Table Actelion Ltd Secondary Progressive Multiple Sclerosis Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2013-2018)
Figure Actelion Ltd Secondary Progressive Multiple Sclerosis Drug Sales Growth Rate (2013-2018)
Figure Actelion Ltd Secondary Progressive Multiple Sclerosis Drug Sales Market Share in United States (2013-2018)
Figure Actelion Ltd Secondary Progressive Multiple Sclerosis Drug Revenue Market Share in United States (2013-2018)
Table Biogen, Inc. Basic Information List
Table Biogen, Inc. Secondary Progressive Multiple Sclerosis Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2013-2018)
Figure Biogen, Inc. Secondary Progressive Multiple Sclerosis Drug Sales Growth Rate (2013-2018)
Figure Biogen, Inc. Secondary Progressive Multiple Sclerosis Drug Sales Market Share in United States (2013-2018)
Figure Biogen, Inc. Secondary Progressive Multiple Sclerosis Drug Revenue Market Share in United States (2013-2018)
Table F. Hoffmann-La Roche Ltd. Basic Information List
Table F. Hoffmann-La Roche Ltd. Secondary Progressive Multiple Sclerosis Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2013-2018)
Figure F. Hoffmann-La Roche Ltd. Secondary Progressive Multiple Sclerosis Drug Sales Growth Rate (2013-2018)
Figure F. Hoffmann-La Roche Ltd. Secondary Progressive Multiple Sclerosis Drug Sales Market Share in United States (2013-2018)
Figure F. Hoffmann-La Roche Ltd. Secondary Progressive Multiple Sclerosis Drug Revenue Market Share in United States (2013-2018)
Table Genzyme Corporation Basic Information List
Table Genzyme Corporation Secondary Progressive Multiple Sclerosis Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2013-2018)
Figure Genzyme Corporation Secondary Progressive Multiple Sclerosis Drug Sales Growth Rate (2013-2018)
Figure Genzyme Corporation Secondary Progressive Multiple Sclerosis Drug Sales Market Share in United States (2013-2018)
Figure Genzyme Corporation Secondary Progressive Multiple Sclerosis Drug Revenue Market Share in United States (2013-2018)
Table Glialogix, Inc. Basic Information List
Table Glialogix, Inc. Secondary Progressive Multiple Sclerosis Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2013-2018)
Figure Glialogix, Inc. Secondary Progressive Multiple Sclerosis Drug Sales Growth Rate (2013-2018)
Figure Glialogix, Inc. Secondary Progressive Multiple Sclerosis Drug Sales Market Share in United States (2013-2018)
Figure Glialogix, Inc. Secondary Progressive Multiple Sclerosis Drug Revenue Market Share in United States (2013-2018)
Table Immune Response BioPharma, Inc. Basic Information List
Table Immune Response BioPharma, Inc. Secondary Progressive Multiple Sclerosis Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2013-2018)
Figure Immune Response BioPharma, Inc. Secondary Progressive Multiple Sclerosis Drug Sales Growth Rate (2013-2018)
Figure Immune Response BioPharma, Inc. Secondary Progressive Multiple Sclerosis Drug Sales Market Share in United States (2013-2018)
Figure Immune Response BioPharma, Inc. Secondary Progressive Multiple Sclerosis Drug Revenue Market Share in United States (2013-2018)
Table Innate Immunotherapeutics Ltd Basic Information List
Table Innate Immunotherapeutics Ltd Secondary Progressive Multiple Sclerosis Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2013-2018)
Figure Innate Immunotherapeutics Ltd Secondary Progressive Multiple Sclerosis Drug Sales Growth Rate (2013-2018)
Figure Innate Immunotherapeutics Ltd Secondary Progressive Multiple Sclerosis Drug Sales Market Share in United States (2013-2018)
Figure Innate Immunotherapeutics Ltd Secondary Progressive Multiple Sclerosis Drug Revenue Market Share in United States (2013-2018)
Table Kyorin Pharmaceutical Co., Ltd. Basic Information List
Table Kyorin Pharmaceutical Co., Ltd. Secondary Progressive Multiple Sclerosis Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2013-2018)
Figure Kyorin Pharmaceutical Co., Ltd. Secondary Progressive Multiple Sclerosis Drug Sales Growth Rate (2013-2018)
Figure Kyorin Pharmaceutical Co., Ltd. Secondary Progressive Multiple Sclerosis Drug Sales Market Share in United States (2013-2018)
Figure Kyorin Pharmaceutical Co., Ltd. Secondary Progressive Multiple Sclerosis Drug Revenue Market Share in United States (2013-2018)
Table Mallinckrodt Plc Basic Information List
Table Mallinckrodt Plc Secondary Progressive Multiple Sclerosis Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2013-2018)
Figure Mallinckrodt Plc Secondary Progressive Multiple Sclerosis Drug Sales Growth Rate (2013-2018)
Figure Mallinckrodt Plc Secondary Progressive Multiple Sclerosis Drug Sales Market Share in United States (2013-2018)
Figure Mallinckrodt Plc Secondary Progressive Multiple Sclerosis Drug Revenue Market Share in United States (2013-2018)
Table MedDay SA Basic Information List
Table MedImmune, LLC Basic Information List
Table Merck KGaA Basic Information List
Table Meta-IQ ApS Basic Information List
Table Novartis AG Basic Information List
Table Opexa Therapeutics, Inc. Basic Information List
Table Xenetic Biosciences (UK) Limited Basic Information List
Table Production Base and Market Concentration Rate of Raw Material
Figure Price Trend of Key Raw Materials
Table Key Suppliers of Raw Materials
Figure Manufacturing Cost Structure of Secondary Progressive Multiple Sclerosis Drug
Figure Manufacturing Process Analysis of Secondary Progressive Multiple Sclerosis Drug
Figure Secondary Progressive Multiple Sclerosis Drug Industrial Chain Analysis
Table Raw Materials Sources of Secondary Progressive Multiple Sclerosis Drug Major Players/Suppliers in 2017
Table Major Buyers of Secondary Progressive Multiple Sclerosis Drug
Table Distributors/Traders List
Figure United States Secondary Progressive Multiple Sclerosis Drug Sales Volume (K Pcs) and Growth Rate Forecast (2018-2025)
Figure United States Secondary Progressive Multiple Sclerosis Drug Revenue (Million USD) and Growth Rate Forecast (2018-2025)
Figure United States Secondary Progressive Multiple Sclerosis Drug Price (USD/Pcs) Trend Forecast (2018-2025)
Table United States Secondary Progressive Multiple Sclerosis Drug Sales Volume (K Pcs) Forecast by Type (2018-2025)
Figure United States Secondary Progressive Multiple Sclerosis Drug Sales Volume (K Pcs) Forecast by Type (2018-2025)
Figure United States Secondary Progressive Multiple Sclerosis Drug Sales Volume (K Pcs) Forecast by Type in 2025
Table United States Secondary Progressive Multiple Sclerosis Drug Sales Volume (K Pcs) Forecast by Application (2018-2025)
Figure United States Secondary Progressive Multiple Sclerosis Drug Sales Volume (K Pcs) Forecast by Application (2018-2025)
Figure United States Secondary Progressive Multiple Sclerosis Drug Sales Volume (K Pcs) Forecast by Application in 2025
Table United States Secondary Progressive Multiple Sclerosis Drug Sales Volume (K Pcs) Forecast by Region (2018-2025)
Table United States Secondary Progressive Multiple Sclerosis Drug Sales Volume Share Forecast by Region (2018-2025)
Figure United States Secondary Progressive Multiple Sclerosis Drug Sales Volume Share Forecast by Region (2018-2025)
Figure United States Secondary Progressive Multiple Sclerosis Drug Sales Volume Share Forecast by Region in 2025
Table Research Programs/Design for This Report
Figure Bottom-up and Top-down Approaches for This Report
Figure Data Triangulation
Table Key Data Information from Secondary Sources
Table Key Data Information from Primary Sources

More Publications

Need Help?

Ask a Question

Market Reports

All Categories